Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Genetically Engineered Animals
Knockout Mice
Knockout Rats
Knockin Mice
Knockin Rats
Transgenic Mice
Transgenic Rats
Model Generation Techniques
Turboknockout<sup>®</sup> Gene Targeting
ES Cell Gene Targeting
Targeted Gene Editing
Regular Transgenic
PiggyBac Transgenesis
BAC Transgenic
Research Models
HUGO-GT™ Humanized Mice
Cre Mouse Lines
Humanized Target Gene Models
Metabolic Disease Models
Ophthalmic Disease Models
Neurological Disease Models
Autoimmune Disease Models
Immunodeficient Mouse Models
Humanized Immune System Mouse Models
Oncology & Immuno-oncology Models
Covid-19 Mouse Models
MouseAtlas Model Library
Knockout Cell Line Product Catalog
Tumor Cell Line Product Catalog
AAV Standard Product Catalog
Animal Supporting Services
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
BAC Modification
Custom Cell Line Models
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Point Mutation Cell Lines
Overexpression Cell Lines
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Lentivirus Packaging
Adenovirus Packaging
CRO Services
By Therapeutic Area
Oncology
Ophthalmology
Neuroscience
Metabolic & Cardiovascular Diseases
Autoimmune & Inflammatory
By Drug Type
AI-Powered AAV Discovery
Gene Therapy
Oligonucleotide Therapy
Antibody Therapy
Cell Immunotherapy
Resources
Promotion
Events & Webinars
Newsroom
Blogs & Insights
Resource Vault
Reference Databases
Peer-Reviewed Citations
Rare Disease Data Center
AbSeek
Cell iGeneEditor™ System
OriCell
Quality
Facility Overview
Animal Health & Welfare
Health Reports
About Us
Corporate Overview
Our Partners
Careers
Contact Us
Login
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
Full Name
Email
Phone Number
Organization
Job Role
Country
Catalog Type
Product Name
Additional Comments
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
C57BL/6JCya-Atxn1em1/Cya
Common Name:
Atxn1-KO
Product ID:
S-KO-04198
Background:
C57BL/6JCya
Product Type
Age
Genotype
Sex
Quantity
Price:
Contact for Pricing
Basic Information
Strain Name
Atxn1-KO
Strain ID
KOCMP-20238-Atxn1-B6J-VA
Gene Name
Atxn1
Product ID
S-KO-04198
Gene Alias
2900016G23Rik; Atx1; Gm10786; Sca1
Background
C57BL/6JCya
NCBI ID
20238
Modification
Conventional knockout
Chromosome
13
Phenotype
MGI:104783
Document
Click here to download >>
Application
--
More
Rare Disease Data Center >>
Note
Note: When using this mouse strain in a publication, please cite “C57BL/6JCya-Atxn1em1/Cya mice (Catalog S-KO-04198) were purchased from Cyagen.”
Strain Description
Ensembl Number
ENSMUST00000180110
NCBI RefSeq
NM_001199305
Target Region
Exon 7
Size of Effective Region
~3.2 kb
Detailed Document
Click here to download >>
Overview of Gene Research
Atxn1, encoding Ataxin-1, is a dosage-sensitive gene [2,7]. Mutations in it are closely related to spinocerebellar ataxia type 1 (SCA1), an autosomal dominant neurodegenerative disease [1,2,4,5]. The normal function of ATXN1 may be involved in protein-protein interactions, and wild-type polyglutamine regions in ATXN1 are implicated in stabilizing these interactions [3].

In SCA1, the expanded CAG repeat in ATXN1 leads to polyglutamine-expanded ATXN1. These polyQ-expanded ATXN1 form intranuclear inclusion bodies (IIBs) that sequester RNA molecules, potentially affecting ribosome function, protein synthesis, and proteome stability [1]. Reducing the nuclear localization of mutant ATXN1 using CRISPR-Cas9 to alter the nuclear localization sequence (K772T) in mice improves SCA1-like phenotypes such as motor and cognitive deficits, and premature lethality, and also corrects transcriptomic profiles in different brain regions [5]. Additionally, Cas9 editing of ATXN1 in SCA1 mouse models and human iPSC-derived neurons shows potential as a treatment modality, as a 20% reduction of ATXN1 improved behavior deficits without increasing inflammatory markers [4]. Intermediate-length polyglutamine expansions in ATXN1 are associated with amyotrophic lateral sclerosis (ALS), especially in C9orf72 expansion carriers, and in functional experiments, ATXN1 affects TDP-43 nucleocytoplasmic ratio and enhances ALS phenotypes in Drosophila [6,8]. miR760 can bind to the 5' untranslated region of ATXN1, regulating its expression, and delivery of AAV-expressing miR760 in the cerebellum reduces ATXN1 levels in vivo and mitigates motor coordination deficits in an SCA1 mouse model [7].

In conclusion, studies on Atxn1, especially through mouse models, have revealed its crucial role in SCA1 and its potential association with ALS. These findings provide insights into the molecular pathogenesis of these neurodegenerative diseases and suggest potential therapeutic strategies, such as gene-editing and miRNA-based therapies.

References:

1. Gkekas, Ioannis, Vagiona, Aimilia-Christina, Pechlivanis, Nikolaos, Andrade-Navarro, Miguel A, Petrakis, Spyros. 2023. Intranuclear inclusions of polyQ-expanded ATXN1 sequester RNA molecules. In Frontiers in molecular neuroscience, 16, 1280546. doi:10.3389/fnmol.2023.1280546. https://pubmed.ncbi.nlm.nih.gov/38125008/

2. Xie, Mingyi, Swanson, Maurice S. . UTteR control through miRs: fine-tuning ATXN1 levels to prevent ataxia. In Genes & development, 34, 1107-1109. doi:10.1101/gad.343020.120. https://pubmed.ncbi.nlm.nih.gov/32873576/

3. Rocha, Sara, Vieira, Jorge, Vázquez, Noé, Sousa, André D, Vieira, Cristina P. 2019. ATXN1 N-terminal region explains the binding differences of wild-type and expanded forms. In BMC medical genomics, 12, 145. doi:10.1186/s12920-019-0594-4. https://pubmed.ncbi.nlm.nih.gov/31655597/

4. Fagan, Kelly J, Chillon, Guillem, Carrell, Ellie M, Waxman, Elisa A, Davidson, Beverly L. 2024. Cas9 editing of ATXN1 in a spinocerebellar ataxia type 1 mice and human iPSC-derived neurons. In Molecular therapy. Nucleic acids, 35, 102317. doi:10.1016/j.omtn.2024.102317. https://pubmed.ncbi.nlm.nih.gov/39314800/

5. Handler, Hillary P, Duvick, Lisa, Mitchell, Jason S, Zoghbi, Huda Y, Orr, Harry T. 2022. Decreasing mutant ATXN1 nuclear localization improves a spectrum of SCA1-like phenotypes and brain region transcriptomic profiles. In Neuron, 111, 493-507.e6. doi:10.1016/j.neuron.2022.11.017. https://pubmed.ncbi.nlm.nih.gov/36577403/

6. Lattante, Serena, Pomponi, Maria Grazia, Conte, Amelia, Zollino, Marcella, Sabatelli, Mario. 2017. ATXN1 intermediate-length polyglutamine expansions are associated with amyotrophic lateral sclerosis. In Neurobiology of aging, 64, 157.e1-157.e5. doi:10.1016/j.neurobiolaging.2017.11.011. https://pubmed.ncbi.nlm.nih.gov/29274668/

7. Nitschke, Larissa, Tewari, Ambika, Coffin, Stephanie L, Liu, Zhandong, Zoghbi, Huda Y. 2020. miR760 regulates ATXN1 levels via interaction with its 5' untranslated region. In Genes & development, 34, 1147-1160. doi:10.1101/gad.339317.120. https://pubmed.ncbi.nlm.nih.gov/32763910/

8. Tazelaar, Gijs H P, Boeynaems, Steven, De Decker, Mathias, Veldink, Jan H, van Es, Michael A. 2020. ATXN1 repeat expansions confer risk for amyotrophic lateral sclerosis and contribute to TDP-43 mislocalization. In Brain communications, 2, fcaa064. doi:10.1093/braincomms/fcaa064. https://pubmed.ncbi.nlm.nih.gov/32954321/

Quality Control Standard
Sperm Test

Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.

Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.

Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0338
Email:
animal-service@cyagen.com
service@cyagen.us
CRO Services
OncologyOphthalmologyNeuroscienceMetabolic & CardiovascularAutoimmune & InflammatoryGene TherapyAntibody Therapy
About Us
Corporate OverviewOur PartnersCareersContact Us
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest